The current PE ratio of XOMA cannot be calculated, as the latest EPS of -$3.44 is negative. XOMA's last PE ratio on record was 20.12 in September 2022.
The mean historical PE ratio of XOMA over the last nine years is 43.73. Looking back at the last nine years, XOMA's PE ratio peaked in the Sep 2021 quarter at 130.26, with a price of $24.75 and an EPS of $0.19. The Mar 2018 quarter marked the lowest point at 13.67, with a price of $20.23 and an EPS of $1.48.
Maximum annual decrease: -43.85% in 2021
Year | PE ratio | Change |
---|---|---|
2023 | N/A | N/A |
2022 | N/A | N/A |
2021 | 30.22 | -43.85% |
2020 | 53.82 | N/A |
2019 | N/A | N/A |
2018 | N/A | N/A |
2017 | 47.47 | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
Stock name | PE ratio | Market cap |
---|---|---|
NVS Novartis AG | 11.25 | $194.15B |
REGN Regeneron Pharmaceuticals Inc | 16.23 | $77.13B |
PFE Pfizer Inc | 34.68 | $149.38B |
ABBV AbbVie Inc | 60.97 | $310.27B |
LLY ELI LILLY & Co | 82.64 | $728.85B |
EBS Emergent BioSolutions Inc | N/A | $438.89M |
TEVA Teva Pharmaceutical Industries Ltd | N/A | $25.03B |
XOMA XOMA Corp | N/A | $319.67M |
The current price to earnings ratio of XOMA cannot be determined, as its EPS of -$3.44 is negative.
The average PE ratio for XOMA stock over the past 5 years is 51.66.
Over the last nine years, the quarterly PE ratio reached its highest level at 130.26 in the Sep 2021 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.